# A Study of Ramucirumab Combination Therapy in Japanese Participants Who Have Advanced Stomach Cancer

> **NCT02359058** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 18 (actual)

## Conditions studied

- Stomach Neoplasms

## Interventions

- **DRUG:** Ramucirumab
- **DRUG:** Capecitabine
- **DRUG:** Cisplatin
- **DRUG:** S-1
- **DRUG:** Oxaliplatin

## Key facts

- **NCT ID:** NCT02359058
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-02
- **Primary completion:** 2016-07
- **Final completion:** 2016-11
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2018-01-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02359058

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02359058, "A Study of Ramucirumab Combination Therapy in Japanese Participants Who Have Advanced Stomach Cancer". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT02359058. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*